Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab self-administration via autoinjector/pen versus healthcare provider administration via prefilled syringe in postmenopausal osteoporosis
2017-003512-40Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of romosozumab in postmenopausal osteoporosis (2 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in bone mineral density at the lumbar spine. Started Dec 2017; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2017-003512-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003512-40.